×
About 2,278 results

ALLMedicine™ Liposarcoma Center

Research & Reviews  802 results

Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma
https://clinicaltrials.gov/ct2/show/NCT05080790

Oct 18th, 2021 - Soft-tissue sarcomas (STS) are a heterogeneous group of malignancies characterized by both their relatively low incidence and their poor prognosis, encompassing more than 60 distinct diagnoses. Leiomyosarcoma (LMS), together with liposarcoma, is o...

Dedifferentiated liposarcoma with abrupt transition of low-grade and high-grade dediffe...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504230
International Journal of Immunopathology and Pharmacology; Wen Y, He X et. al.

Oct 9th, 2021 - Dedifferentiated liposarcoma is a unique subtype of liposarcoma, which has obvious histological heterogeneity. In affected patients, the condition typically manifests as the dedifferentiation of high-grade histological morphology, but it may also ...

Overview of malignant soft-tissue sarcomas of the limbs.
https://doi.org/10.1016/j.crad.2021.08.011
Clinical Radiology; Renn A, Adejolu M et. al.

Oct 6th, 2021 - Although soft-tissue masses are common, sarcomas are rare malignant neoplasms showing variable mesenchymal differentiation and can occur at any anatomical site. Limb soft-tissue sarcomas (STS) are rare, but often lethal tumours. Although there are...

MYL2 as a potential predictive biomarker for rhabdomyosarcoma.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8483830
Medicine Wang J, Gao S et. al.

Oct 2nd, 2021 - Rhabdomyosarcoma (RMS) is a common malignant soft tissue sarcoma, which is the third most common soft tissue sarcoma after malignant fibrohistoma and liposarcoma. The discovery of potential postbiomarkers could lead to early and more effective tre...

Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants
https://clinicaltrials.gov/ct2/show/NCT04939701

Oct 1st, 2021 - The study is comprised of 2 phases. Phase 1 (dose escalation) includes participants with solid tumors known to express New York esophageal squamous cell carcinoma 1 (NY-ESO-1). Phase 2 (ASP0739 as single agent and in combination with Pembrolizumab...

see more →

Drugs  8 results see all →

Clinicaltrials.gov  15 results

Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma
https://clinicaltrials.gov/ct2/show/NCT05080790

Oct 18th, 2021 - Soft-tissue sarcomas (STS) are a heterogeneous group of malignancies characterized by both their relatively low incidence and their poor prognosis, encompassing more than 60 distinct diagnoses. Leiomyosarcoma (LMS), together with liposarcoma, is o...

Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants
https://clinicaltrials.gov/ct2/show/NCT04939701

Oct 1st, 2021 - The study is comprised of 2 phases. Phase 1 (dose escalation) includes participants with solid tumors known to express New York esophageal squamous cell carcinoma 1 (NY-ESO-1). Phase 2 (ASP0739 as single agent and in combination with Pembrolizumab...

Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
https://clinicaltrials.gov/ct2/show/NCT01532687

Sep 27th, 2021 - PRIMARY OBJECTIVES: I. To investigate whether treatment with gemcitabine (gemcitabine hydrochloride) plus pazopanib (pazopanib hydrochloride) improves the median progression-free survival (PFS) of patients with metastatic soft tissue sarcoma when ...

Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma
https://clinicaltrials.gov/ct2/show/NCT04979442

Aug 27th, 2021 - Approximately 160 patients will be randomly assigned in a 1:1 ratio to receive milademetan or trabectedin. Randomization will be stratified by the ECOG performance status (0 or 1) and number of prior treatments (≤ 2 or > 2) for the patient's lipos...

Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery
https://clinicaltrials.gov/ct2/show/NCT02249949

Aug 18th, 2021 - PRIMARY OBJECTIVES: I. To determine the confirmed response rate for efatutazone dihydrochloride (efatutazone) in patients with advanced myxoid liposarcoma whose disease has progressed on at least one prior therapy. SECONDARY OBJECTIVES: I. To asse...

see more →

News  79 results

Dr. D'Angelo on Bempegaldesleukin/Nivolumab Combo in Sarcomas
https://www.onclive.com/view/dr-dangelo-on-bempegaldesleukin-nivolumab-combo-in-sarcomas

Oct 6th, 2021 - Sandra P. D’Angelo, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the results of a pilot study investigating the combination of bempegaldesleukin (NKTR-214) plus nivolumab (Opdivo) in patients with sarcomas. The m...

Key Advances in Sarcoma Lead to More Personalized Medicine Efforts
https://www.onclive.com/view/key-advances-in-sarcoma-lead-to-more-personalized-medicine-efforts

Oct 6th, 2021 - Jonathan C. Trent, MD, PhD Soft tissue sarcoma treatments have significantly advanced within the past year with new available agents, others in the pipeline, and the continued search for biomarkers to make treatment more personalized for patients...

Dr. Schwartz on the Benefit of Dose Reduced Nivolumab/Ipilimumab in Metastatic Sarcomas
https://www.onclive.com/view/dr-schwartz-on-the-benefit-of-dose-reduced-nivolumab-ipilimumab-in-metastatic-sarcomas

Oct 6th, 2021 - Gary K. Schwartz, MD, a professor of medicine, chief of the Division of Hematology​/Oncology, and deputy director of Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses the benefit of dose reducing ipilimuma...

Moffitt Expert Emphasizes Need to Improve Sarcoma Diagnoses
https://www.onclive.com/view/moffitt-expert-emphasizes-need-to-improve-sarcoma-diagnoses

Oct 6th, 2021 - Pathology is the cornerstone of precision medicine, explained Marilyn M. Bui, MD, PhD, who added that, as a whole, the health care specialty needs to step it up in the diagnosis of sarcomas and the differentiation between the various histological ...

New Mechanism of Action Results Renew Interest in Eribulin
https://www.onclive.com/view/new-mechanism-of-action-findings-renew-interest-in-eribulin

Jul 16th, 2021 - There has been renewed interest in eribulin mesylate (Halaven) following its FDA approval for advanced or unresectable liposarcoma and with the introduction of a growing body of preclinical work suggesting the agent has a novel anti—mesenchymal me...

see more →

Patient Education  7 results see all →